Media - Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):

 

Middle area:

Press releases 2010

Press releases are intended to journalists, analysts and investors.

Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology in Diabetes and Related Disorders

December 21, 2010

Sanofi-aventis and Avila Therapeutics Sign Global Alliance to Develop Targeted Covalent Oncology Drugs

December 20, 2010

Sanofi-aventis and Merck KGaA Sign Agreement to Jointly Investigate Novel Combinations Against Cancer

December 17, 2010

Composition of the Board of Directors of sanofi-aventis

December 15, 2010

Sanofi-aventis appoints Dr. Elias Zerhouni, President, Global Research & Development

December 14, 2010

Sanofi-aventis Extends Tender Offer for all Outstanding Shares of Genzyme

December 13, 2010

Sanofi-aventis announces Wayne Pisano’s retirement and appoints Olivier Charmeil Senior Vice President Vaccines

December 10, 2010

Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions

November 08, 2010

Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical Development

November 04, 2010

Sanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Platform in China

October 28, 2010

Resilient sales and business EPS in Q3 2010

October 28, 2010

Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis

October 26, 2010

Sanofi-aventis Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Genzyme

October 20, 2010

Sanofi-aventis Establishes Research Collaboration with Harvard University

October 18, 2010

Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients

October 15, 2010

Final Results from Phase II Study Confirm BSI-201 (Iniparib) Prolongs Survival in Metastatic Triple Negative Breast Cancer

October 10, 2010

Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash

October 04, 2010

Jevtana® Improves Survival in Advanced Prostate Cancer Patients

October 01, 2010

Once-Daily Lixisenatide in Combination with Basal Insulin Demonstrates Significant Improvement in Glucose Control

September 30, 2010

Sanofi Pasteur to Acquire VaxDesign, a U.S. biotechnology company

September 27, 2010

Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology

September 23, 2010

Clinical Update on TAMARIS Phase III Trial for NV1FGF

September 22, 2010

Sanofi-aventis presents its innovative blood glucose monitoring devices to enhance self-management of diabetes

September 21, 2010

Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes

September 20, 2010

Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients with Type 2 Diabetes

September 20, 2010

Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

September 08, 2010

Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization

September 01, 2010

Teriflunomide Significantly Reduced Annualized Relapse Rate and was well Tolerated in MS patients

August 30, 2010

Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme

August 29, 2010

Multaq® First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation

August 29, 2010

Sanofi-aventis Comments on Injunctive Relief Hearing Regarding Lovenox®

August 26, 2010

Availability on line of the Group’s half-year financial report for 2010

July 30, 2010

EPS growth in Q2 2010

July 29, 2010

Sanofi-aventis and Merck appoint Raul Kohan as CEO for the new Animal Health joint venture

July 27, 2010

Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium in the U.S.

July 23, 2010

Sanofi Pasteur Inaugurates its Hi-Tech Influenza Vaccine Facility in Shenzhen, China

July 23, 2010

Jevtana® (cabazitaxel) Injection Now Available in the U.S.

July 19, 2010

Sanofi-aventis and JDRF Form Partnership to Improve Therapies, Work Toward Cure for Type 1 Diabetes

July 01, 2010

Rifapentine is granted Orphan Drug Status by European Commission for Treatment of Tuberculosis

July 01, 2010

Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company

June 30, 2010

Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin

June 26, 2010

Improved Outcomes for Patients Treated with Lantus® and Apidra® Regimen Compared with Sliding Scale Insulin

June 25, 2010

Sanofi-aventis and Metabolex enter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II Diabetes

June 25, 2010

Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

June 22, 2010

Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review

June 17, 2010

Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases

June 08, 2010

Teriflunomide in adjunct to interferon beta significantly improved outcomes of Multiple Sclerosis patients

June 05, 2010

Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology

June 04, 2010

The Charité University in Berlin and sanofi-aventis Sign an Innovative Research Cooperation Agreement

May 31, 2010

Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan

May 28, 2010

Updated Phase 3 Survival Results with Cabazitaxel in Patients with Advanced Hormone-Refractory Prostate Cancer, Presented at ASCO

May 27, 2010

Sanofi-aventis Establishes Strategic Alliance with MIT’s Center for Biomedical Innovation

May 26, 2010

Sanofi-aventis Wins the 2010 Global Business Coalition Core Competence Award for its Innovative Malaria Access to Medicines Program

May 25, 2010

Sanofi-aventis to reinforce its Consumer Health Care platform in Poland

May 19, 2010

Combined General Shareholder Meeting of May 17, 2010

May 17, 2010

Sanofi-aventis announces the creation of the “Sanofi Espoir” Corporate Foundation

May 17, 2010

Sanofi-aventis initiates 10,000 patient study with Multaq® in permanent atrial fibrillation

May 12, 2010

Sanofi-aventis and Glenmark Pharmaceuticals Sign License Agreement on Novel Agents to treat Chronic Pain

May 03, 2010

Change in sanofi-aventis Executive Committee

April 30, 2010

Q1 2010: A good first quarter

April 29, 2010

Sanofi-aventis Announces Court Decision Resolving Eloxatin® U.S. Patent Litigation

April 23, 2010

Sanofi-aventis’ Combined General Shareholder Meeting to be held May 17, 2010

April 20, 2010

Once Daily Lixisenatide (AVE 0010) Given as Monotherapy Successfully Meets Phase III Study Endpoints in Diabetes

April 15, 2010

Sanofi Pasteur Partners with U.S. Naval Medical Research Center to Advance Development of Travelers’ Diarrhea Vaccine

April 12, 2010

Board of Directors of sanofi-aventis

April 09, 2010

Sanofi-aventis successfully completes a tap on its October 2014 bond for 500 million Euros

April 08, 2010

Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement on Novel Regenerative Compound to Treat Diabetes

April 08, 2010

Sanofi-aventis makes updated settlement announcement regarding Eloxatin® U.S. Patent litigation

April 06, 2010

Sanofi-aventis amends its Alliance Agreement with Warner Chilcott regarding Actonel® (risedronate sodium) in the United States and Puerto Rico

April 05, 2010

Sanofi-aventis announces settlement of Eloxatin® U.S. patent litigation

April 01, 2010

Sanofi-aventis invests €150 million in France and continues its Change towards Biotechnologies

March 31, 2010

Sanofi-aventis & AgaMatrix enter into worldwide agreement on blood glucose monitoring (BGM) solutions

March 31, 2010

Multaq® receives positive recommendation by NICE in new appraisal consultation document

March 30, 2010

Sanofi-aventis confirms Quality and Supply of Plavix®, Iscover® and Clopidogrel Winthrop®

March 26, 2010

DuoPlavin®/DuoCover® Dual antiplatelet combination tablet newly approved in the European Union

March 24, 2010

Filing of the 2009 U.S. Form 20-F and French “Document de Référence” and Annual Financial Report

March 12, 2010

Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc.

March 11, 2010

Sanofi-aventis and Merck to create a Global Leader in Animal Health

March 09, 2010

Cabazitaxel increased survival for patients with advanced hormone-refractory prostate cancer

March 04, 2010

Board of Directors of sanofi-aventis

March 02, 2010

Sanofi Pasteur’s A(H1N1) vaccine HUMENZA® recommended by European Medicines Agency

February 19, 2010

Sanofi-aventis strengthens commitment to Research in France through partnership with AVIESAN

February 17, 2010

“My child matters” supports seven new childhood cancer care projects

February 15, 2010

Sanofi-aventis delivers double-digit EPS¹ growth in 2009 as the Transformation program progresses

February 10, 2010

Sanofi-aventis successfully completes tender offer for Chattem, Inc.

February 09, 2010

Sanofi-aventis Signs Agreements to Establish New Consumer Healthcare Joint Venture in China with Minsheng Pharmaceutical Group

January 29, 2010

Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer

January 26, 2010

Sanofi-aventis and employees unite for the victims of Haiti

January 21, 2010

Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections

January 11, 2010

Sanofi-aventis Commences Tender Offer for all Outstanding Shares of Chattem, Inc.

January 11, 2010

Sanofi-aventis reinforces its Consumer Health Care Management

January 08, 2010

Right area:

Search

Search

 
   

Filter by date

 
 
 
 

© Sanofi 2004-2014 - All rights reserved - Update: January 17, 2014